Archive | January, 2015

Hot Life Science Investor Mandate 1: Family Office Seeking Life Science Investments Globally

8 Jan

A family office founded by a successful medical device entrepreneur can make investments ranging from approximately $500,000 to $100 million into companies and due to its funding structure has no requirements for holding period or capital structure. The firm makes investments in the forms of equity, controlling interest, in-licensing, MBO/LBO, growth capital and is also willing to co-invest. The firm is looking for companies located around the globe and makes around 5-15 investments in a given year.

The firm is looking for companies in sectors of Biotech Therapeutics and Diagnostics, Medtech, Heathcare IT, R&D Services, and Biotech Other. The firm is willing to consider all indications including orphan diseases, though they have some additional interest/experience is areas of Women’s Health, GI, Oncology, Cardiovascular, and Personalized Medicine including Proteomics and Genomics. The firm is most interested in companies that are in Phase II or later, nearing commercialization where the firm is capable of utilizing its operating company to scale up the company’s sales, marketing and distribution. That being said the firm has made earlier stage investments in the past and is open to considering highly innovative and compelling early stage companies. The firm is also interested in companies developing consumables/reagents, service providers, food and nutraceuticals.

The firm looks to work with management teams with experience and grit and generally looks to take a board seat although it is not a requirement. The firm looks to leverage the use of its operating company to assist the company’s sales marketing and distribution efforts as well as providing assistance in operations management.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 2: Chinese Private Equity Firm Looking Globally for Life Science Innovation Capable of Entering Chinese Market

8 Jan

Allocation Information:

An investment holding company based in China specializes in equity investment, debt financing, and equity investment services. With capital commitment from both public and private investors, the firm currently has total assets under management of over RMB 1 billion (US$160.52 million). Since 2001, the firm has made equity investments in 189 seed-stage projects, 65 growth-stage projects, and 42 mature-stage projects. The firm focuses on pre-series A to series A investments of up to US$2 million; as well as on series B to pre-IPO investments of up to US$50 million. Allocations are made in equity and convertible notes. The firm seeks to invest in China-based companies or foreign businesses with China-based partners or seeking to enter the Chinese market.

Sectors & Subsectors of Interest:

The firm is interested in innovative technologies across various sectors including life sciences. Within life sciences, the firm is open to all technologies including small molecule therapeutics, biologics, medical devices, and diagnostics. The firm invests in all stages of development with a special interest in clinical-stage assets.

Company & Management Team Requirements:

The firm is looking for experienced management teams and typically syndicates with other investors and takes 20%-30% minority stake in a financing round. One of the firm’s subsidiaries operates on an incubator model that offers capital, mentorship, and business advisory services to investee companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Hot Life Science Investor Mandate 3: CVC of Large Pharma Looking for Therapeutics and Companion Diagnostics

8 Jan

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase I of clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com